Search Within

Chrisann Kyi Kyi

  1. "Journal of Clinical Oncology"
Formats
  1. Meeting Abstract (12)
Groups
  1. Department of Medicine (12)
  2. GDMT, Medicine (12)
  3. Gynecologic Medicine Service (12)
  4. Gynecology Disease Management Team (12)
  5. Solid Tumor Oncology Division (12)
  6. Hematologic Malignancies, Division of (8)

More Groups

People
  1. Carol Aghajanian (8)
  2. Roisin O'Cearbhaill (8)
  3. Claire Friedman (7)
  4. Dmitriy Zamarin (7)
  5. Rachel Grisham (7)
  6. Vicky Makker (6)

More People

Years
  1. 2024 (2)
  2. 2022 (3)
  3. 2020 (4)
  4. 2019 (1)
  5. 2018 (2)
Publications
  1. Journal of Clinical Oncology (12)
Publishers
  1. American Society of Clinical Oncology (12)

Results (12)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC)
    Meeting Abstract

    Jazaeri, A. A.; Grisham, R. N.; Gaillard, S.; How, J. A.; Hazard, S.; Musso, L.; Kyi, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
    Meeting Abstract

    Kyi, C.; Van Dongen, M.; Rottey, S.; Bermejo, I. M.; Mittag, D.; Gouveia, D.; Bol, K.; Yan, C.; Joe, A. K.; Laus, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Pattern of disease in recurrent cervical cancer associated with response to pembrolizumab
    Meeting Abstract

    Miller, K.; Filippova, O. T.; Hayes, S. A.; Abu-Rustum, N.; Aghajanian, C.; Broach, V.; Ellenson, L. H.; Jewell, E. L.; Kyi, C.; Lakhman, Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR plus ) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Iasonos, A.; Girshman, J.; Cadoo, K. A.; Kyi, C.; Makker, V.; Cohen, S. M.; O'Cearbhaill, R. E.; Sabbatini, P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Gastric-type adenocarcinoma of the cervix: Genomic drivers and clinical outcomes
    Meeting Abstract

    Sassine, D.; Straubhar, A. M.; Aghajanian, C.; Alektiar, K. M.; Broach, V.; Cadoo, K. A.; Jewell, E. L.; Kyi, C.; Leitao, M. M.; Mueller, J. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies
    Meeting Abstract

    Drake, C. G.; Johnson, M. L.; Spira, A. I.; Manji, G. A.; Carbone, D. P.; Henick, B. S.; Ingham, M.; Liao, C. Y.; Roychowdhury, S.; Kyi, C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save